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PROPHYLAXIS FOR HERPETIC VIRUSES POST AUTOLOGOUS STEM CELL
TRANSPLANTS: A RETROSPECTIVE REVIEW AT A REGIONAL TRANS-
PLANT CENTER
Bohnenblust, E.1, Ramey, S.1, Schisler, N.1, Thompson, L.1,
Schammel, C.1, Dillard, T.2, Fanning, S.2, Webb, S.2 1Furman Univer-
sity, Greenville, SC; 2Cancer Centers of the Carolinas, Greenville, SC
Following hematopoietic stem cell transplantation as a treatment
for hematological disease, prophylactic care for herpetic infections in
immunocompromised patients is essential. Acyclovir is a widely pre-
scribed anti-viral medication that can reduce the risk of HSV, CMV,
EBV, and VZV reactivation in post-transplant patients. The benefits
of acyclovir include low cost and low toxicity. However, the usage,
dosage, and duration of acyclovir treatment vary among treatment
centers. To evaluate the efficacy of one acyclovir prophylaxis proto-
col, we performed a retrospective review from 2002–2007 of all pa-
tients (n 5 150) who underwent single or tandem autologous
peripheral blood stem cell transplantations at the Cancer Centers
of the Carolinas (CCC). The CCC’s standard operating procedure
suggests that patients receive 400 mg of acyclovir BID three times
per week following transplantation until the patient’s CD4 count
reaches the 400 cells/mliter threshold. CD4 count testing began at
200 days with subsequent tests every 100 days until patients reached
threshold. Only 19% of patients were tested to threshold in this
study. Acyclovir prophylaxis was terminated prior to threshold in
30% of patients. CD4 counts performed at 200 days post transplant,
had a median value of 232 cells/mliter. Within the 28 patient cadre
that were monitored for CD4 counts, 53% reached threshold within
199 days, 67%within 299 days, and 82%within 399 days post-trans-
plantation. The remaining 17% reached threshold 400 or more days
post-transplantation. These results suggest reassessment of the CD4
count threshold at critical time junctures in the reconstitution of the
immune system is necessary to avoid indefinite acyclovir therapy. A
myriad of issues influence patient compliance and provider response
to results. Some of these factors include patient non-compliance, in-
complete testing, results not available for office visits andmanual sys-
tems for ordering and analysis. The conclusion of this study focuses
on areas for process improvement.With the development of a FACT
compliant EMR (Electronic Medical Record), our center will create
transplant specific triggers to assure appointments are made and re-
sults obtained for provider assessment. Additional data pointsmay be
developed to track HSV, VZV, CMV and EBV antibody status as
well as the incidence of relevant viral infections and concomitant an-
tiviral therapy. Computerized results will allow on-going tracking,
follow-up and analysis.432
SYMPTOMS AND PERSONALITY TRAITS IN PATIENTSWITH HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION
Na, Y.H.1, Yoo, M.H.1, Han, E.K.1, Lee, J.Y.1, Seo, G.E.1, Lee, J.H.1,
Song, B.E.2, Kim, K.S.1 1St. Mary’s Hospital, Seoul, Korea; 2Catholic
Medical Center, Seoul, Korea
The purpose of this study is to investigate the personality of pa-
tients with HSCT, to identify the symptom experience shown by pe-
riods of transplantation, and to present basic database in order to
formulate more effective, optimum nursing interventions for
HSCT. The subjects of this study were 100 patients who were 18
years of age and older and underwent HSCT at the HSCT center
in S Hospital of C University located in Seoul. The data were col-
lected between October 1, 2007 and August 15, 2008. The personal-
ity trait was measured once at the next day of hospitalization for
transplantation, by using of the shortened version of NEO-PI-R,
which was translated and adapted in Korean. The symptom experi-
ence was investigated three times ‘pre-transplant stage(T1)’, ‘trans-
plant stage(T2)’ and ‘post-transplant stage(T3)’ of HSCT for each
subject, by using of a tool translated and adapted in Korean from
Symptom Occurrence(Frequency), Intensity & Distress-Stem Cell
Transplantation (SFID–SCT). The results of this study are as fol-lows; Over 80% of the patients showed changes in taste, loss of ap-
petite, mouth dryness, fatigue, diarrhea, nausea, insomnia, and
mouth sores in the period of T2. Changes in taste and loss of appetite
were highest in the scores of symptom occurance(SO), while changes
in taste were highest in the scores of symptom distress(SD). As for
the personality factors of the patients withHSCT, the score of agree-
ableness was highest. There was no significant difference in person-
ality traits according to the types of transplantation and disorders.
Among the five personality factors of the patients with HSCT, neu-
roticism and extraversion affected the symptoms. Neuroticism as
a factor affected almost all the periods of transplantation for the
symptom intensity(SI) and SD, except the SI of T3. Extraversion af-
fected all the periods of transplantation for the SI and SD. Conclu-
sively, the SO, SI and SD were highest in T2, and the neuroticism
and extraversion among the personality traits of the patients with
HSCT affected the symptoms. Therefore, it is necessary to develop
nursing interventions appropriate for patients who had higher neu-
roticism and extraversion. As with the SO, SI and SD according to
the transplantation periods in patients with HSCT, changes in taste
and loss of appetite were highest all the periods of transplantation. It
is offered that further development and evaluation research of effec-
tive diet programs for patients with HSCT are necessary.433
ENHANCING THE SAFETY OF HIGH RISK MEDICATION ADMINISTRATION
ON AN INPATIENT STEM CELL TRANSPLANT UNIT
Johnson, M., White, A., Jacob, R., Johnston, P. The University of Md
Anderson Cancer Center, Houston, TX
Background:Medication administration errors are an increasing
concern in health care. High dose chemotherapy, biologicmodifying
agents, and medications used in the prevention and treatment of
GVHD account for a portion of these errors. The effects of these
medication errors can be lethal when they are administered incor-
rectly. With the increasing use of agency and float pool staff, there
may be nurses administering these agents who are not familiar
with the correct procedure for administration or the side effects as-
sociatedwith them.The Joint Commission has identifiedmedication
safety as one of its 2009 National Patient Safety goals. Nine patient
safety solutions have been previously identified by the International
Steering Committee. These solutions are to be used as a guide in
evaluating and re-designing delivery of care to focus on prevention
of medication errors and safe medication administration. In imple-
menting these solutions into our model of care for our 52 bed impa-
tient Stem Cell Transplant and Cellular Therapy Unit, we have
identified the need for an additional measure to decrease the risk
of medication administration errors with those particular high risk
medications.
Interventions: A tool was developed to aid in the administration
of chemotherapy, biologic modifying agents, and medications used
in the prevention and treatment of GVHD. These tools included
the name of the drug, the tubing and filter to be used, the vital
sign schedule, the side effects, and any miscellaneous information
that needed to be included for each specific medication. The tool
was then placed in each of the chemotherapy preparation areas where
the nurses would be able to see and access the information easily.
Results: An evaluation tool was administered to the nurses on
SCTCT unit to determine if the tool was effectively making it easier
to access the correct information about the medications that they
were administering.
Recommendations:The creation of a chemotherapy/medication
chart on our inpatient SCTCT unit has assisted in decreasing the
number of medication errors as well as increasing the awareness of
nursing staff in regards to safe administration of these agents.434
UTILITY OF INSUFLONe CATHETERS AFTER PEDIATRIC HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION: TAKING THE PAIN OUT OF SUBCU-
TANEOUS INJECTIONS
Prokopiou, C., Koontz, S.E., Rosipal, N., Worth, L.L., Petropoulos, D.,
Kelly, S.S., Lee, D.A., Cooper, L.J.N. Children’s Cancer Hospital at the
University of Texas M. D. Anderson Cancer Center, Houston, TX
Poster Session-II 153Pediatric hematopoietic stem cell transplantation (HSCT) is
a lengthy, dynamic and complex medical procedure requiring multi-
ple invasive procedures. Although the procedure is accepted to treat
and ameliorate a variety of medical conditions, the process has dele-
terious physiological and psychological consequences. One of the
more common medical problems experienced by HSCT patients is
pain. Causes of pain in this patient population are multi-factorial,
but frequently can be attributable to conditioning regimen-related
toxicities (e.g., mucositis), medical procedures (e.g., catheter inser-
tions), and medication administration (e.g., subcutaneous injections).
As a result, the pain experienced by HSCT recipients significantly
and adversely impacts their medical course, performance status and
quality of life as well as the quality of life of those around them. Ef-
forts to lessen the duration and decrease the intensity of pain experi-
enced by children undergoingHSCT are crucial to successful patient
outcomes and improved quality of life. We have implemented one
method to address an aspect of this medical need through the use
of an indwelling catheter (insuflone; manufactured by Unomedical,
Denmark) as a means of administering subcutaneous medications.
Prior to the initiation of therapies administered subcutaneously, an
insuflon catheter is placed by the nurse. Training for catheter place-
ment is straightforward and can be accomplished within 30 minutes
using a preceptor model. The catheter is allowed to remain in place
for up to seven days and avoids daily insertion of a needle into the sub-
cutaneous tissue to deliver prescribed medications. We will summa-
rize our experience with using insuflon catheters in HSCT patients
for the administration of Neupogen (filgrastim) and Lovenox
(enoxaparin). Educational materials for health care professionals as
well as for patients and their caregivers will be presented. Addition-
ally, as a result of our success with insuflon catheters in our HSCT
recipients, policies and procedures for expanding the use of this cath-
eter to other patient populations as well as for the administration of
additional agents will be shared. This information is expected to be
of widespread interest since by decreasing the pain and anxiety sur-
rounding daily subcutaneous injections we have positively impacted
the quality of life of patients and care givers as well as strengthened
the healthcare professional-patient relationship.PHARMACY435
EFFICACY OF PALIFERMIN FOR MUCOSITIS IN HEMATOPOIETIC STEM
CELL TRANSPLANT RECIPIENTS
Campaign, J.E.1, Ippoliti, C.2 1University of New Mexico, Albuquerque,
NM; 2NewYork-Presbyterian Hospital Weill Cornell Medical College,
New York, NY
Palifermin is recommended by the American Cancer Society to re-
duce the incidence and severity of mucositis in patients undergoing
high-dose chemotherapy with total body irradiation (TBI) prior to
autologous stemcell transplant (SCT). Since approval, results of stud-
ies of palifermin have been mixed. This study was undertaken to de-
termine the impact of palifermin on the incidence and severity of
mucositis in a high-risk population of SCT recipients who received
a variety of conditioning regimens at a large teaching institution.
We retrospectively compared outcomes of 18 palifermin-treated
SCT recipients with those of 33 patients managed prior to palifermin
availability. Paliferminwasdosed 60micrograms/kg/day IV for 3 days
prior to chemotherapy and 3 days after stem cell infusion. Controls
were matched based on type of malignancy, preparative regimen,
and high-risk features (dialysis, CrCl \60 mL/min, Karnofsky
performance score\70, allogeneic stem cell source). All patients re-
ceived peripheral stem cells, and 16.7% of palifermin patients and
18.2% of controls received those from an allogeneic source. Multiple
myeloma was the most common diagnosis, and melphalan was the
most common conditioning agent (both 76.4%).Only 11%of palifer-
min patients and 12.1%of controls received TBI.Median duration of
mucositis was 17 (3–42) days for palifermin patients vs. 12 (4–41) days
for controls (p 5 0.06). A total of 66.7% of palifermin patients vs.
51.5% of controls experienced grade 3–4 mucositis (p 5 0.38), for
a median duration of 9 (4–33) vs. 7 (3–18) days, respectively (p 5
0.05). Palifermin-treated patients did not experience a shortermedian
length of stay, and there was no significant difference in duration of
opioid or parenteral nutrition use. Based on these findings, palifermindoes not appear to provide significant benefit in the SCT population
at this institution to justify its cost. Further research is warranted to
determine under which conditions palifermin provides positive
outcomes.436
EVALUATING CLINICAL PHARMACY SERVICES IN A LEUKEMIA/BMT MED-
ICAL INTERVENTION CLINIC: A PILOT PROJECT
Warkentin, D.I.1, Lacaria, K.1, Partovi, N.1, Berryman, K.1, Smith, C.2
1Vancouver Coastal Health, Vancouver, BC, Canada; 2BC Cancer
Agency, Vancouver, BC, Canada
Introduction: There has been a significant increase in the number
of patients requiring either chemotherapy or HSCT being treated as
outpatients at the Leukemia/BMT Program of B.C. These patients
are complex medically and are on a greater number of medications.
Clinical pharmacy services are provided to the inpatient Leukemia/
BMT unit but not the outpatient clinic. Various studies have demon-
strated that the provision of clinical pharmacy services can significantly
reduce the occurrence of adverse drug events and improve patient
outcomes. Also the availability of clinical pharmacists can reduce the
occurrence of medication errors and significantly reduce drug costs,
thought the promotion of rational and cost effective medication use.
Main Thesis: The Leukemia/BMT Outpatient clinic received
full time clinical pharmacist for a six-month trial. During this evalu-
ation period and as part of quality improvement efforts by pharmacy
administration, services have been documented manually and by
using a personal digital assistant (PDA). Data fields as described by
Hepler and Strand, currently used in the inpatient unit, were used
and all other interventions were documented manually1. Interven-
tions were categorized into the following: patient access, patient
safety, cost containment, improved quality of patient care, reduced
workload and improved staff morale. SUMMARY This is the first
Canadian study to document considerable contributions of a clinical
pharmacy in an outpatient leukemia/HSCT clinic providing direct
patient care. These findings indicate clinical pharmacy services are
essential in providing quality patient care in an outpatient setting.
Conclusion: Permanent funding for a clinical pharmacist in the
Outpatient Leukemia/BMT Program is justified.437
SUBCUTANEOUS ADMINISTRATION OF ALEMTUZUMAB (CAMPATH-1H)
IS WELL TOLERATED AND EFFECTIVE
Lawrence, J., Bleesing, J., Filipovich, A., Jodele, S., Mehta, P., Davies, S.
Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Alemtuzumab (campath-1H) is a humanized anti-CD52monoclo-
nal antibody that has been successfully used as part of conditioning
regimes for HSCT to prevent GVHD. Intravenous alemtuzumab
is associated with frequent infusion related toxicity. We hypothe-
sized that subcutaneous alemtuzumab would be better tolerated
and effective. We have treated 32 patients receiving HSCT for
mainly non-malignant diseases with a reduced-intensity preparatory
regime including campath-1H, fludarabine, and melphalan. Sixteen
patients were given intravenous alemtuzumab, 14 subcutaneous
alemtuzumab and 2 a combination of 2 doses subcutaneous alemtu-
zumab followed by 2 doses of intravenous alemtuzumab. Fifteen pa-
tients had immune deficiency diseases, 6 metabolic disorders, 6
HLH, 3 Schwachman Diamond syndrome, 1 Kostmann’s syndrome
and 1 MDS. Age range was 4 months to 15 years. All patients re-
ceived bone marrow except one cord blood. Twenty seven donors
were unrelated, 4 matched siblings, and 1 unrelated donor umbilical
cord. Patients who received subcutaneous or intravenous alemtuzu-
mab showed similar drops in lymphocyte counts at Day15 and Day
17 after alemtuzumab. Thirteen of 16 patients receiving intravenous
alemtuzumab had fever associated with administration, 10 had rash
and 11 reported other toxicities as rigors, chills, hives, pruritus,
tachycardia, hypotension, nausea, vomiting, and headache. In the
group receiving subcutaneous alemtuzumab, 7 of 16 developed fe-
vers, 2 developed rash and 3 reported other toxicities as nausea,
chills, and tachycardia. The incidence of GVHD was similar in the
two groups, 5 of 16 in the intravenous group and 8 of 16 in the sub-
cutaneous group. Survival was similar in the two groups, with 16 of
18 surviving at day 100 in the intravenous group and 15 of 16 in the
